ITF Therapeutics

I soon found out not only what it was, but that it was perfect for me thanks to my experience in my first industry role. If a physician, patient, or pharmacist called to inquire about something, I was on the other side of that phone. I discovered that I l

Heading into our second year of operations, two powerful family stories stick in my mind as signposts to guide us on our mission. The first is a video sent to us by the mother of a ten-year-old boy with DMD. The towheaded boy looks right at the camera and

One thing we know is this: There's no single solution to change the face of Duchenne. We all have to continue working really hard - together - to keep making strides against this disease. We need teamwork, we need trust, and we need honest discussions to

As Head of Human Resources, I have the privilege of supporting and overseeing our growth and development. While HR often brings to mind paperwork and logistics like retirement plans and health insurance - important pieces of the puzzle - my true focus is

Early in my career, I had the chance to watch and learn from Henri Termeer who was CEO of Genzyme and a role model to me and many others. Genzyme was a pioneering company that created unique and impactful medicines for people living with rare diseases. He

My team works with insurance companies to help them understand the value that rare disease medications can bring to patients and the role of new therapies in the evolving DMD treatment paradigm. Speaking for all of ITF Therapeutics, and my team in particu

Our main clinical study, EPIDYS, included 179 patients - one of the largest trials in DMD to date - so a good deal of data exists to inform treatment decisions. In the study, 179 ambulant boys six years of age or older received glucocorticosteroid treatme